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ABSTRACT
Background: As transcatheter aortic valve replacement (TAVR) becomes a preferred treatment option for patients
with aortic valve stenosis, and demand for TAVR increases, it is imperative that length of stay (LOS) is reduced while
maintaining safety and effectiveness.
Local Problem: As TAVR procedures have become less invasive and more streamlined, current protocols have not
been updated to reﬂect today’s postprocedure requirements.
Methods: The next-day discharge (NDD) protocol was established using available literature. A convenience sample
was evaluated for NDD protocol inclusion during aortic multidisciplinary team conference using predetermined
inclusion and exclusion criteria. Length of stay for NDD protocol participants was compared with LOS from a retrospective convenience sample of patients undergoing TAVR in the time frame mirroring NDD protocol initiation of
the year prior.
Interventions: Patients meeting inclusion criteria were enrolled in the NDD protocol with a goal of discharge to home
on postprocedural day 1 by 2:00 p.m. The NDD protocol included preprocedure expectation setting, prescheduled
same-day postprocedure imaging, and discharge priority on postprocedure day 1.
Results: There is a signiﬁcant difference in LOS between the NDD eligible retrospective and prospective groups. The
prospective group has a signiﬁcantly lower LOS than the retrospective group (M = 1.6 vs 2.1, respectively; p = .0454).
Conclusions: An NDD protocol can help reduce LOS after TAVR in appropriately selected patients. Further protocol
revision will be required to optimize LOS outcomes.
Keywords: NDD; next-day discharge; process improvement; quality improvement; length of stay; LOS; TAVR; transcatheter aortic valve replacement.
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Background and local problem
Transcatheter aortic valve replacement (TAVR) is an attractive option for patients with severe aortic stenosis
and is now the treatment of choice for many patients
(Carroll et al., 2020). As TAVR becomes more common,
ensuring efﬁciency in postprocedural length of stay (LOS)
is imperative (Mack et al., 2019) to ensure availability of
resources. Transcatheter aortic valve replacement procedures, historically, followed postoperative surgical
valve protocols with an average 6-day LOS (Wood et al.,
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2019). As TAVR became less invasive and more streamlined, the necessary postprocedure hospitalization period has decreased. However, many hospitals have not
reimagined the postprocedural protocols to ﬁt within
today’s changing environment.
As hospitals prepare to perform more TAVR procedures to meet the growing demand, strategies will need
to be implemented to effectively manage an expanding
capacity. Currently, there is a gap in the literature for upto-date postprocedure care protocols of TAVR patients,
which allows for signiﬁcant variations in the LOS (Spies &
Whisenant, 2014). Previous studies have suggested that
next-day discharge (NDD) is both feasible and safe
(Alkahalil et al., 2018; Kamioka et al., 2018; Kontronias et al.,
2018; Lauck et al., 2016; Sud et al., 2017) and provide a
stable framework in which to base new protocols. Although work on decreasing postprocedure LOS has begun, there remains much room for improvement through
standardization of postprocedural care. This quality
Month 2022

· Volume 00 · Number 00

1

© 2022 American Association of Nurse Practitioners. Unauthorized reproduction of this article is prohibited.

Quality Improvement Report
improvement initiative was aimed at standardizing a
postprocedure pathway to reduce and remove barriers to
NDD by ensuring timeliness of postprocedural care. Interventions to accomplish this will include preidentiﬁcation of patients appropriate for NDD,
prescheduling of postprocedure imaging, and preeducation to prepare patients for NDD.

Purpose of project
It was postulated that replication of minimalist TAVR
clinical pathways, along with the addition of a prescreening tool to predict the patient population within
the TAVR subset that would beneﬁt from an NDD protocol,
would allow for decreased LOS. The purpose of this project was to determine whether implementation of the
NDD protocol, modeled after previously successful clinical pathways, is an effective tool in reducing LOS in a large
intercity hospital.

Literature review
Current literature supports the safety and feasibility of
NDD protocol development (Alkahalil et al., 2018; Kamioka
et al., 2018; Lauck et al., 2016; Marcantuono et al., 2014).
However, there are currently no published evidencebased guidelines for an NDD protocol for patients undergoing TAVR. The impact of NDD after transfemoral
TAVR was studied by Lauck et al. (2019), who suggested
that some of the chief drivers of cost maintenance included management of in-hospital complications, device
price, and length of hospital stay. Although complications
and device price are improving, they are not predictable
and amenable to intervention. However, postprocedure
LOS is an aspect of care that provides opportunity for cost
reduction.
Lauck et al. (2019) found that patient proﬁles were
different for NDD candidates versus non-NDD candidates.
Discharge disposition to home rather than a rehabilitation facility was a characteristic of a patient most
appropriate for NDD because they experienced a lower
rate of hospital readmission in a 30-day period and had
comparable rates of 30-day mortality as those with a
longer LOS (Lauck et al., 2019). Lauck et al. (2019) concluded that a comprehensive pathway streamlining preprocedure, peri-procedure, and postprocedure care may
help to reduce costs while also optimizing outcomes. A
standardized “minimalist” clinical pathway demonstrated success in NDD while at the same time demonstrating no increased risk of 30-day mortality or morbidity
(Lauck et al., 2019) and resulting in superior one-year
outcomes as compared with non-NDD patients (Kamioka
et al., 2018). Replication of the outcomes reported from
previously successful clinical pathway discharge programs for post-TAVR patients will require a multidisciplinary team effort to achieve the desired outcomes of
safe, effective, and efﬁcient care (Wood et al, 2019).
2
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Methods
Before protocol implementation, approval from the institutional review board (IRB) was requested and granted.
This quality improvement project was considered exempt
by the IRB. Participants appropriate for inclusion in the
NDD protocol were identiﬁed using a convenience sample
and determined using the TAVR NDD Eligibility Form
(Appendix A, Supplemental Digital Content 1, http://links.
lww.com/JAANP/A153). This screening tool was developed
for use within the NDD protocol because there was no
currently available screening tool appropriate for this
protocol (see example of protocol workﬂow in Appendix
B, Supplemental Digital Content 2, http://links.lww.
com/JAANP/A154). Patient’s LOS was measured through
review of the electronic medical record (EMR). Length of
stay for NDD protocol participants was compared with
LOS from a retrospective convenience sample of patients
undergoing TAVR from February 1, 2020 through July 30,
2020. The prospective sample was a convenience sample
evaluated for protocol inclusion during Aortic Multidisciplinary Team Conference (MDT).

Intervention
The NDD protocol was developed for use in an 877-bed
intercity hospital. Protocol inclusion screening began on
February 1, 2021 and concluded on July 30, 2021. Screening
took place during aortic MDT using the TAVR NDD Eligibility Form. Eligibility was documented in the MDT meeting minutes in the patient’s EMR to serve as an indicator
of enrollment. Speciﬁc inclusion and exclusion criteria
were used as detailed in Table 1.
Patients eligible for participation in the NDD protocol
were scheduled as either a ﬁrst or second daily TAVR
procedure based on physician and schedule availability.
A patient list of planned TAVR procedures requiring
same-day postprocedural transthoracic echocardiogram
(TTE) was sent by email to the noninvasive department
manager and scheduler to ensure timely scheduling of
post-TAVR TTE.
The morning after successful TAVR procedure, patients
were evaluated by the nurse practitioner, Structural Heart
Disease (SHD) Fellow, and/or Interventional Cardiologist
Attending Physician to determine discharge readiness.
Considerations that necessitated withdrawal from the
NDD protocol included, but were not limited to, new
conduction disturbance on ECG, hemodynamic instability,
vascular access complication, patients’ subjective report,
and/or deranged laboratory values. If no contraindications to discharge were noted, echocardiogram was
reviewed by either the SHD fellow or the attending cardiologist, and patients were cleared for discharge if no
abnormalities were noted. Patients were discharged per
standard hospital protocol by the Hospitalist Service.
Discharge goal was 2:00 p.m. on postprocedure day 1.
www.jaanp.com
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Table 1. Inclusion and exclusion criteria for NDD protocol
Exclusion criteria
• <18 years old
• Require alternative access
s Trans-axillary
s Trans-aortic
s Trans-carotid
s Trans-apical
• Scheduled for self-expanding valve in absence of permanent
pacemaker (Lilly et al., 2020)
• Inpatient status immediately before TAVR
• Pre-existing conduction disturbance
s R BBB
s Second-degree heart block
• Frailty score 2 or greater
s Frailty indicators include
■ BADL = />6
■ 5-m walk <6 s
■ Albumin = 3.5 or higher

Inclusion criteria
• 18 years or older
• Transfemoral or transcaval access
• For patients without a preexisting
permanent pacemaker
s Scheduled to receive balloon
expandable valve
• Outpatient status before procedure
• No preexisting conduction disease
without presence of permanent
pacemaker (right bundle branch
block, second-degree heart block;
Lilly et al., 2020)
• Frailty score of 1 or less
s Frailty indicators include
■ BADL = />6
■ 5-m walk <6 s
■ Albumin = 3.5 or higher

Results
All analyses were done using SAS 9.4 and statistical signiﬁcance was set at p < .05.
There was a total of 122 retrospective patients. Fiftyone patients (42%) qualiﬁed for the NDD protocol and 71
patients (58%) did not qualify. There were a total of 126
patients evaluated for prospective protocol inclusion.
Fifty-ﬁve patients (44%) qualiﬁed for inclusion and 71
patients (56%) did not qualify for inclusion. Average total
LOS was calculated in days. Difference between total LOS
was done using Wilcoxon rank sum test due to
nonnormality.
Mean total LOS for the entire retrospective sample was
3.4 days, whereas the mean LOS for all prospective patients was 2.4 days. There is a signiﬁcant difference in LOS
between the retrospective and prospective groups (p =
.0016). The prospective group had a signiﬁcantly lower
LOS than the retrospective group (Table 2).

Mean LOS for the retrospective group who were not
eligible for NDD inclusion was 4.2 days. Mean LOS for the
retrospective group, who would have been eligible for the
NDD protocol, was 2.1 days. There is a signiﬁcant difference in LOS between the NDD-eligible retrospective and
noneligible retrospective groups (p < .0001). The noneligible group has a signiﬁcantly longer LOS than the eligible group (Table 3).
Mean LOS for prospective patients who did qualify for
NDD protocol was 1.6 days. Mean LOS for retrospective
group who would have qualiﬁed for NDD protocol was
2.1 days. There was a signiﬁcant difference in LOS between
the NDD-eligible retrospective and prospective groups
(p = .0454). The prospective group has a signiﬁcantly lower
LOS than the retrospective group (Table 4).
Of the 55 prospective patients qualifying for NDD, 19
(36%) were successfully discharged on postprocedure
day 1 by 2:00 p.m. Of the remaining 36 NDD protocol

Table 2. Summary of retrospective versus prospective (ALL) group
Group

N

Variable

Mean

SD

Median

Minimum

Maximum

Retro

122

Total LOS (days)

3.4

3.7

2.1

0.4

20.3

80.7

88.4

50.5

10.5

487.3

2.4

3.0

1.4

0.8

20.5

58.5

70.8

33.0

19.6

491.1

Total LOS (h)
Pros

126

Total LOS (days)
Total LOS (h)

Note: There is a significant difference in LOS between the retrospective and prospective groups. The prospective group has a significantly lower LOS than the
retrospective group (p = .0016).
LOS = length of stay.
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Table 3. Summary of noneligible versus eligible retrospective patients
NDD Eligible

N

Variable

No

71

Total LOS (days)

Mean

Total LOS (h)
Yes

51

Total LOS (days)
Total LOS (h)

SD

Median

Minimum

Maximum

4.2

4.3

2.3

0.4

20.3

102.1

103.4

56.1

10.5

487.3

2.1

2.0

1.4

1.0

14.5

51.1

49.1

33.9

24.0

347.0

Note: There is a significant difference in the LOS between the retrospective NDD eligible and retrospective noneligible groups. The noneligible group has a significantly
longer LOS than the eligible group, p < .0001.
LOS = length of stay; NDD = next day discharge.

patients who were not discharged home by the target
time of 2:00 p.m., the most common reasons included new
conduction disturbances (4 patients, 7%), postprocedure
groin complication (3 patients, 5.5%), delay of discharge
order from discharging physician (12 patients, 21.8%),
delay in clearance for discharge from SHD team (4 patients, 7%), patient delay (4 patients, 7%), postprocedure
complications that were not access related (2 patients,
3.6%), postprocedure TTE not completed day of procedure
(2 patients, 3.6%), and other reasons (3 patients, 5.5%;
Table 5). Of the 71 patients who were determined not to be
NDD eligible, 4 (5.6%) were discharged home by 2:00 p.m.
on postprocedure day 1.
The TAVR eligibility form had an 89% reliability in determining patients appropriate for NDD. Of the 55 patients
qualifying for NDD, 6 patients (11%) had events resulting
in withdrawal from the NDD protocol. These events included new conduction disturbance requiring further
evaluation with an electrophysiology study (N = 1), femoral access site complications (hematoma, pseudo aneurysm, etc.; N = 3), allergic reaction to protamine during
procedure requiring ICU care (N = 1), ﬂash pulmonary
edema requiring ICU care (N = 1), and inpatient TAVR
procedure after acute illness requiring hospitalization
(N = 1).

Discussion
Implementation of the NDD protocol was able to show a
statistically signiﬁcant reduction in LOS for patients who
were determined eligible for inclusion. Reductions in LOS
were demonstrated in all groups.
The entire retrospective sample compared with the
entire prospective sample demonstrated a mean LOS
reduction of 1.0 day (p = .0016). The retrospective sample
happened to fall during the beginning of the COVID-19
pandemic, which may have had an impact on LOS for that
particular group. Additionally, patients were electively
postponing TAVR procedures at this time if disease severity allowed. This may have directly affected LOS during
the retrospective time frame because it is feasible to
consider that only the sickest patients were being treated
at that speciﬁc time.
Length of stay differences were noted between the
retrospective eligible and the retrospective noneligible
groups. The LOS difference was a mean of 1.9 days (p <
.0001). This difference helps to deﬁne the expected LOS
difference between patients who would qualify for NDD
compared with those who would not.
The retrospective eligible group versus the prospective
eligible group demonstrated a mean LOS reduction of
0.5 days (p = .0454). This reduction demonstrates that

Table 4. Summary retrospective eligible versus prospective eligible
Group

N

Variable

Retro

51

Pros

55

Mean

Std Dev

Median

Minimum

Maximum

Total LOS (d)

2.1

2.0

1.4

1.0

14.5

Total LOS (h)

51.1

49.1

33.9

24.0

347.7

Total LOS (d)

1.6

1.0

1.3

1.0

6.4

Total LOS (h)

39.2

25.0

30.9

22.9

154.4

Note: There is a significant difference in LOS between retrospective NDD eligible and prospective NDD eligible group. The prospective group has a significantly lower
LOS than the retrospective group, p < .0454.
LOS = length of stay; NDD = next-day discharge.
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Table 5. Reasons prospective eligible patients
were not discharged by 2:00 p.m
n

%

New conduction disturbances

4

7

Groin complication

3

5.5

12

21.8

Delay in cardiac clearance

4

7

Patient delay/no ride

4

7

Non access related postprocedure
complication

2

3.6

Postprocedure TTE delay

2

3.6

Other

3

5.5

Delay in discharge order

preidentiﬁcation of appropriate patients, prescheduling of
postprocedure imaging, and early patient expectation setting can signiﬁcantly decrease LOS. Although the reduction
in LOS cannot be entirely attributed to implementation of
the NDD protocol, speciﬁc portions of the protocol, including
preidentiﬁcation of appropriate patients and prescheduling
of postprocedure imaging, seem to be effective modalities in
beginning to reduce unnecessary delays to discharge.
The prescreening eligibility form was evaluated to determine the accuracy with which it is able to predict a patient’s actual readiness for NDD. There was a small subset of
patients who did not initially qualify for inclusion in the NDD
protocol who were able to be discharged by the target time
of postoperative day 1. This suggests that it may be reasonable to reconsider some of the inclusion criteria to determine which items may be expanded to allow for greater
inclusion. Some of these items include reducing frailty
measure inclusion to include patients with a frailty score of 2
and including patients with lower risk, preexisting conduction disturbances, such as ﬁrst-degree atrioventricular
nodal block and pre-existing right bundle branch blocks.
With an 89% success rate, the screening tool could continue
to be effectively used to help predict which patients would
appropriate for NDD.
Of the factors found to be signiﬁcant in delaying discharge, patient hesitancy, lack of transportation home on
postprocedure day 1, conduction disturbances requiring
further telemetry monitoring or electrophysiology study,
groin complications, and lack of timely discharge from the
discharging physician were the most common. The most
anticipated delay of discharge was delay in postprocedure imaging; however, this was not found to be as
signiﬁcant as previously thought and, in fact, the largest
identiﬁed delay was timely rounding and entry of discharge orders from the discharging providers.
There is room for continued improvement in patient
education and expectation setting that could potentially
Journal of the American Association of Nurse Practitioners

have a signiﬁcant impact on reducing unnecessary delays
to discharge. For example, the NDD protocol included
patient education surrounding the plan for NDD by 2:00
p.m. This would allow for patients and their families to
ensure transportation would be available. Many patients
still reported that they were unaware of the anticipated
NDD and, therefore, did not have a ride secured. Patients
also reported not being comfortable with NDD because
they expected to spend two to three days in the hospital.
Another area of the protocol that fell short of the goal
was timely discharge by the discharging providers. The
delay in provider discharge was one of the most challenging areas encountered during the implementation of
the protocol. Further work to ensure timely and expedited
discharge in conjunction with the Hospitalist team is
imperative to successfully reduce LOS.
Length of stay data were shared with the nursing staff
and physician staff collectively to help demonstrate the
importance of continuing to work on cost reduction
strategies through eliminating unnecessary barriers to
discharge. More work will need to be done to effectively
determine whether a revised version of the NDD protocol
will continue to provide reductions in LOS.

Limitations
Several steps of the protocol, as originally written, were
routinely omitted after implementation, which hindered
the success of the NDD protocol. Additional limitations
included absence of clinical staff buy in and support,
deﬁciency in timely rounding by attending physician staff,
and omission of inclusion eligibility discussion during
MDT conference. Lack of eligibility discussion hindered
the protocol because necessary documentation relating
to eligibility and inclusion was not well disseminated
among the team. Additional limitations included the inability to consistently obtain required postprocedure
imaging on the same day as the procedure and consistent
preprocedure patient preparation for NDD. Many times,
expectations of an extended hospital stay created a
barrier to NDD because reliable rides home were frequently unavailable. Finally, there continues to be a delay
in discharge from the primary Hospitalist group after
patients received cardiac clearance.

Summary
Successful implementation of an NDD protocol will allow
for a more streamlined postprocedure discharge process
for patients undergoing TAVR procedures. In addition to
reducing LOS, additional beneﬁts of an NDD protocol may
include increased ability to accommodate a larger population, decrease in iatrogenic complications as a result
of extended hospitalizations, improvement in ﬁnancial
beneﬁts from shorter LOSs, decreased costs associated
with complications, and reduction of lost revenue from
bed unavailability (Lauck et al., 2019).
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Although we were able to observe a signiﬁcant decrease in the LOS between patients undergoing TAVR
between February and June of 2020 and February and
June of 2021, we cannot effectively say that it was solely
the result of the NDD protocol initiative. However, we have
established a strong platform to continue working from in
an effect to continue to drive the initiative forward. The
original NDD protocol contained many layers of intervention aimed at reducing barriers to timely discharge.
Although successful, there remains room for continued
improvement. Many of the interventions need to be further reimagined to continue to drive down LOS.
Authors’ contributions: C. N. Cusin developed this quality
improvement project, developed the NDD protocol and
screening tool, collected data, and composed the manuscript. P. A. Clark edited and revised the manuscript. C. W.
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manuscript.
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